Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Savara management to meet virtually with JMP Securities » 04:55
07/07/20
07/07
04:55
07/07/20
04:55
SVRA

Savara

$2.14 /

+0.015 (+0.71%)

Virtual Meeting to be…

Virtual Meeting to be held on July 7 hosted by JMP Securities.

ShowHide Related Items >><<
SVRA Savara
$2.14 /

+0.015 (+0.71%)

SVRA Savara
$2.14 /

+0.015 (+0.71%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
SVRA Savara
$2.14 /

+0.015 (+0.71%)

SVRA Savara
$2.14 /

+0.015 (+0.71%)

Over a week ago
Conference/Events
Savara management to meet virtually with JMP Securities » 11:30
06/30/20
06/30
11:30
06/30/20
11:30
SVRA

Savara

$2.58 /

-0.115 (-4.28%)

Virtual Meeting to be…

Virtual Meeting to be held on July 7 hosted by JMP Securities.

ShowHide Related Items >><<
SVRA Savara
$2.58 /

-0.115 (-4.28%)

SVRA Savara
$2.58 /

-0.115 (-4.28%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
SVRA Savara
$2.58 /

-0.115 (-4.28%)

SVRA Savara
$2.58 /

-0.115 (-4.28%)

Over a month ago
Earnings
Savara reports Q1 EPS (27c), consensus (28c) » 16:43
05/07/20
05/07
16:43
05/07/20
16:43
SVRA

Savara

$2.55 /

+0.13 (+5.37%)

As of March 31, 2020,…

As of March 31, 2020, Savara had debt of approximately $25.0 million and cash, cash equivalents, and short-term investments of approximately $105 million. Under the current operating plan, the Company believes this is sufficient capital to fund planned operations into 2022. "With the recent clarity around the IMPALA 2 study design, along with the expansion of our pipeline with the Phase 3 Apulmiq development program, 2020 has kicked off with a strong start," said Rob Neville, Chief Executive Officer, Savara. "We are now working diligently to get these two studies initiated as soon as possible."

ShowHide Related Items >><<
SVRA Savara
$2.55 /

+0.13 (+5.37%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
Syndicate
Savara files to sell 47.93M shares of common stock for holders  16:22
04/17/20
04/17
16:22
04/17/20
16:22
SVRA

Savara

$2.46 /

+0.195 (+8.61%)

 
ShowHide Related Items >><<
SVRA Savara
$2.46 /

+0.195 (+8.61%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
Over a quarter ago
Conference/Events
Savara to host conference call » 08:15
04/03/20
04/03
08:15
04/03/20
08:15
SVRA

Savara

$1.85 /

-0.16 (-7.96%)

Management discusses the…

Management discusses the exclusive license and collaboration agreement with Grifols for Apulmiq, also known as Linhaliq in Europe, a late-stage investigational inhaled antibiotic in Phase 3 development for treatment of non-cystic fibrosis bronchiectasis (NCFB) on a conference call to be held on April 3 at 8:30 am. Webcast Link

ShowHide Related Items >><<
SVRA Savara
$1.85 /

-0.16 (-7.96%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
Hot Stocks
Savara obtains global rights to develop and commercialize Apulmiq » 16:13
04/02/20
04/02
16:13
04/02/20
16:13
SVRA

Savara

$1.86 /

-0.155 (-7.71%)

Savara announced the…

Savara announced the company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq. Also known as Linhaliq in Europe, Apulmiq is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis. Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq. Savara provided an upfront payment and, if regulatory approval is obtained, Grifols will be eligible for regulatory milestone payments as well as royalties and potential tiered sales milestones upon commercialization. The company expects to work with regulatory agencies to plan a confirmatory Phase 3 study.

ShowHide Related Items >><<
SVRA Savara
$1.86 /

-0.155 (-7.71%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
On The Fly
Fly Intel: After-Hours Movers » 19:05
03/30/20
03/30
19:05
03/30/20
19:05
ALPN

Alpine Immune Sciences

$2.62 /

+0.085 (+3.35%)

, CTMX

CytomX Therapeutics

$6.72 /

+0.36 (+5.66%)

, XCUR

Exicure

$1.39 /

+0.07 (+5.30%)

, AAL

American Airlines

$12.25 /

-1.79 (-12.75%)

, RH

RH

$117.68 /

+6.09 (+5.46%)

, EDAP

EDAP TMS

$2.38 /

+0.02 (+0.85%)

, CRON

Cronos Group

$6.36 /

+0.07 (+1.11%)

, AMRN

Amarin

$13.59 /

+0.34 (+2.57%)

, RETA

Reata Pharmaceuticals

$161.72 /

+11.53 (+7.68%)

, SVRA

Savara

$2.33 /

+0.185 (+8.62%)

, DPZ

Domino's Pizza

$344.71 /

+6.26 (+1.85%)

, PLNT

Planet Fitness

$48.70 /

-2.005 (-3.95%)

, GPS

Gap

$7.41 /

-0.38 (-4.88%)

, CROX

Crocs

$17.50 /

-0.61 (-3.37%)

Check out this…

Open Full Text

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$2.62 /

+0.085 (+3.35%)

11/13/19 Piper Sandler
Alpine Immune Sciences price target lowered to $8 from $11 at Piper Jaffray
05/24/19 Piper Sandler
Alpine Immune Sciences Kite pact termination 'a win,' says Piper Jaffray
05/15/19 Piper Sandler
Piper sees broad partnership potential for Alpine after Adaptimmune deal
CTMX CytomX Therapeutics
$6.72 /

+0.36 (+5.66%)

03/24/20 Wedbush
CytomX Therapeutics upgraded to Outperform at Wedbush
03/24/20 Wedbush
CytomX Therapeutics upgraded to Outperform from Neutral at Wedbush
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
CytomX Therapeutics initiated with an Equal Weight at Barclays
XCUR Exicure
$1.39 /

+0.07 (+5.30%)

12/24/19 H.C. Wainwright
Exicure financing reflects growing institutional demand, says H.C. Wainwright
12/11/19 H.C. Wainwright
H.C. Wainwright reiterates Buy on Exicure after 'favorable' clinical data
11/20/19 Guggenheim
Guggenheim starts Exicure with Buy rating, $9 price target
11/20/19 Guggenheim
Exicure initiated with a Buy at Guggenheim
AAL American Airlines
$12.25 /

-1.79 (-12.75%)

03/27/20 Wolfe Research
American Airlines downgraded to Underperform from Peer Perform at Wolfe Research
03/25/20 Deutsche Bank
Deutsche Bank upgrades eight Airlines to Buy on stimulus agreement
03/25/20 Deutsche Bank
American Airlines upgraded to Buy from Hold at Deutsche Bank
03/25/20 Cowen
Mesa Air downgraded to Market Perform at Cowen
RH RH
$117.68 /

+6.09 (+5.46%)

03/27/20 Barclays
RH price target lowered to $131 from $255 at Barclays
03/23/20 Wells Fargo
RH price target lowered to $120 from $240 at Wells Fargo
01/09/20 Guggenheim
Guggenheim adds Best Buy to Best Idea list, ups price target to $100
01/07/20 BofA
Aaron's, Lowe's positioned for outperformance in 2020, says BofA
EDAP EDAP TMS
$2.38 /

+0.02 (+0.85%)

CRON Cronos Group
$6.36 /

+0.07 (+1.11%)

03/04/20
Fly Intel: Top five analyst upgrades
03/04/20 MKM Partners
Cronos Group upgraded to Buy from Neutral at MKM Partners
03/04/20 MKM Partners
Cronos Group upgraded to Buy from Neutral at MKM Partners
03/03/20
Fly Intel: Top five analyst downgrades
AMRN Amarin
$13.59 /

+0.34 (+2.57%)

03/13/20 Goldman Sachs
Amarin upgraded to Buy from Neutral at Goldman Sachs
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Cantor Fitzgerald
Amarin genric filers have 'weak case,' shares could move to $35, says Cantor
03/02/20 Cowen
Cowen starts Amarin at Outperform on market 'meaningfully discounting' Vascepa
RETA Reata Pharmaceuticals
$161.72 /

+11.53 (+7.68%)

02/20/20 Stifel
Reata Pharmaceuticals price target raised to $362 from $305 at Stifel
02/20/20 Baird
Reata Pharmaceuticals price target raised to $283 from $245 at Baird
02/20/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $320 from $314 at Cantor Fitzgerald
02/20/20 Citi
Reata Pharmaceuticals remains a top pick for 2020 at Citi
SVRA Savara
$2.33 /

+0.185 (+8.62%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
DPZ Domino's Pizza
$344.71 /

+6.26 (+1.85%)

03/23/20 Longbow
Domino's Pizza price target raised to $378 from $351 at Longbow
03/19/20
Fly Intel: Top five analyst upgrades
03/19/20 Deutsche Bank
Domino's Pizza upgraded to Hold from Sell at Deutsche Bank
03/19/20 Deutsche Bank
Domino's Pizza upgraded to Hold from Sell at Deutsche Bank
PLNT Planet Fitness
$48.70 /

-2.005 (-3.95%)

03/24/20 Cowen
Planet Fitness price target lowered to $50 from $95 at Cowen
03/19/20 Piper Sandler
Piper not seeing liquidity risk for Planet Fitness amid shutdowns
03/03/20 Cowen
Cowen provides three retail opportunities amidst market pullback
02/26/20 Jefferies
Planet Fitness price target raised to $100 from $90 at Jefferies
GPS Gap
$7.41 /

-0.38 (-4.88%)

03/30/20 Wells Fargo
Gap downgraded to Underweight from Equal Weight at Wells Fargo
03/19/20 Morgan Stanley
Morgan Stanley lowers targets for Gap, Macy's, and four other levered retailers
03/13/20 BMO Capital
Gap price target lowered to $15 from $18 at BMO Capital
03/13/20 MKM Partners
Gap price target lowered to $11 from $19 at MKM Partners
CROX Crocs
$17.50 /

-0.61 (-3.37%)

03/20/20 Piper Sandler
Crocs price target lowered to $24 from $46 at Piper Sandler
02/21/20 Piper Sandler
Crocs recent pullback a buying opportunity, says Piper Sandler
01/15/20 Monness Crespi
Crocs price target raised to $50 from $44 at Monness Crespi
01/15/20 Stifel
Crocs struck bullish tone in ICR meetings, says Stifel
Hot Stocks
Savara terminates enrollment in CF clinical studies due to COVID-19 » 16:09
03/30/20
03/30
16:09
03/30/20
16:09
SVRA

Savara

$2.33 /

+0.185 (+8.62%)

Savara provided an…

Savara provided an update on the impact COVID-19 has had on two of the Company's clinical studies in cystic fibrosis or CF. Due to the COVID-19 pandemic, and out of an abundance of caution for people living with CF and clinical study staff, enrollment has been terminated in the Phase 3 AVAIL and the Phase 2a ENCORE studies. With patient safety at the forefront of the decision, and in accordance with guidelines established by the FDA, efforts will be made to allow enrolled patients to continue with study treatments and site visit protocols, where possible. The AVAIL study is evaluating AeroVanc in people living with CF who have methicillin-resistant Staphylococcus aureus (ung infection. Total target enrollment was 200 patients. The ENCORE study is evaluating Molgradex in nontuberculous mycobacterial lung infection in people living with CF. Total target enrollment was approximately 30 patients and 14 patients are currently enrolled. The company has not experienced disruptions to the planning of a second Phase 3 study of Molgradex for aPAP and continues conversations with the FDA regarding study design and endpoints. Additionally, while the company has not had any supply chain or manufacturing disruptions due to the current COVID-19 pandemic, the situation is being monitored regularly. With a continued and prolonged health crisis, an interruption could occur.

ShowHide Related Items >><<
SVRA Savara
$2.33 /

+0.185 (+8.62%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
Earnings
Savara reports Q4 EPS (72c), consensus (41c) » 16:10
03/12/20
03/12
16:10
03/12/20
16:10
SVRA

Savara

$2.55 /

+0.18 (+7.59%)

As of December 31, 2019,…

As of December 31, 2019, the company had cash of $49.8 million and short-term investments of $72.0 million. Operating expenses for the fourth quarter of 2019 were approximately $31.5 million which included $19.4 million in noncash goodwill impairment charges. "Results from the open-label period of IMPALA reaffirm our strong belief that Molgradex could improve outcomes for patients with aPAP, a rare and debilitating lung disease," said Rob Neville, CEP. "We continue our conversations with the FDA, as our highest priority is to get clarity from the agency regarding the design and endpoints of a second Phase 3 study in aPAP."

ShowHide Related Items >><<
SVRA Savara
$2.55 /

+0.18 (+7.59%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
Hot Stocks
Fly Intel: Pre-market Movers » 09:01
12/31/19
12/31
09:01
12/31/19
09:01
TME

Tencent Music

$11.66 /

-0.28 (-2.35%)

, CLB

Core Laboratories

$47.34 /

+0.38 (+0.81%)

, MDR

McDermott

$0.75 /

-0.75 (-50.00%)

, SDRL

Seadrill

$2.38 /

+0.12 (+5.32%)

, SVRA

Savara

$4.91 /

+3.195 (+186.30%)

, FCEL

FuelCell

$1.68 /

+0.4 (+31.25%)

HIGHER: Tencent Music…

HIGHER: Tencent Music (TME), up 1% after proposing to join a consortium led by Tencent Holdings to acquire a 10% equity stake in Universal Music Group from its parent company, Vivendi (VIVHY), at an enterprise value of EUR30B. TME proposed to invest up to a 10% equity interest in the consortium... Seadrill (SDRL), up 18% after securing a three year contract for each of the AOD II and AOD III in the Middle East, in direct continuation of their current contracts... FuelCell (FCEL), up 24% after beginning commercial operation of the 2.8 megawatt fuel cell project located at the city of Tulare, California's waste water treatment facility. LOWER: Savara (SVRA), down 2% to give back a small part of the big gains seen yesterday after the FDA granted Breakthrough Therapy designation for Molgradex... Core Laboratories (CLB), down 19% after slashing Q4 guidance, guiding below consensus for Q1 and reducing its quarterly dividend... McDermott (MDR), down another 12% after The Wall Street Journal reported late in yesterday's trading that the company is in discussions with lenders to file for bankruptcy within weeks.

ShowHide Related Items >><<
TME Tencent Music
$11.66 /

-0.28 (-2.35%)

11/03/19 TH Data Capital
TH Data Capital expects Tencent Music Q3 revenue to beat consensus
10/18/19 New Street
Tencent Music initiated with a Buy at New Street
10/08/19 China Renaissance
Tencent Music upgraded to Buy from Hold at China Renaissance
09/06/19 Citi
NetEase price target raised to $326 from $301 at Citi
CLB Core Laboratories
$47.34 /

+0.38 (+0.81%)

12/31/19 Cowen
Core Laboratories price target lowered to $39 from $42 at Cowen
12/31/19 JPMorgan
Core Laboratories price target lowered to $47 from $50 at JPMorgan
10/17/19 ABN Amro
Core Laboratories downgraded to Hold from Buy at ABN Amro
07/10/19
Fly Intel: Top five analyst upgrades
MDR McDermott
$0.75 /

-0.75 (-50.00%)

11/05/19 Citi
McDermott bankruptcy risk is rising, Citi says, while cutting target to $1.60
09/20/19 Credit Suisse
McDermott's plans to sell Lummus 'a last resort,' says Credit Suisse
09/19/19 Citi
Citi sees working capital unwind as 'legitimate risk' for McDermott
09/11/19 Citi
McDermott price target lowered to $7 from $11 at Citi
SDRL Seadrill
$2.38 /

+0.12 (+5.32%)

08/13/19
Fly Intel: Top five analyst downgrades
08/13/19 BTIG
Seadrill downgraded to Neutral from Buy at BTIG
SVRA Savara
$4.91 /

+3.195 (+186.30%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
06/13/19 Canaccord
Savara price target lowered to $15 from $22 at Canaccord
06/13/19 H.C. Wainwright
Savara price target lowered to $6 from $22 at H.C. Wainwright
06/13/19 Ladenburg
Savara downgraded to Neutral from Buy at Ladenburg
FCEL FuelCell
$1.68 /

+0.4 (+31.25%)

12/11/19 Craig-Hallum
FuelCell reinstated with a Hold at Craig-Hallum
06/06/19
Fly Intel: Top five analyst downgrades
06/06/19 Oppenheimer
Oppenheimer downgrades FuelCell to Perform on restructuring, CEO exit
06/06/19 Cowen
FuelCell downgraded to Market Perform from Outperform at Cowen

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.